YKL-40 Aggravates Early-Stage Atherosclerosis by Inhibiting Macrophage Apoptosis in an Aven-dependent Way

Wei Huan†, Liu Yandong†, Wang Chao†, Zou Sili†, Bai Jun†, Liao Mingfang†, Chen Yu‡ and Qu Lefeng‡

1Department of Vascular and Endovascular Surgery, Second Affiliated Hospital of Naval Medical University, Shanghai, China, 2Yueyang Hospital of Integrated Traditional Chinese Medicine & Clinical Research Institute of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Objective: programmed cell removal in atherosclerotic plaques plays a crucial role in retarding lesion progression. Macrophage apoptosis has a critical role in PrCR, especially in early-stage lesions. YKL-40 has been shown to be elevated as lesions develop and is closely related to macrophages. This study aimed to determine the effect of YKL-40 on regulating macrophage apoptosis and early-stage atherosclerosis progression.

Research design and Methods: The correlations among the expression level of YKL-40, the area of early-stage plaque, and the macrophage apoptosis rate in plaques have been shown in human carotid atherosclerotic plaques through pathological and molecular biological detection. These results were successively confirmed in vivo (Ldlr−/- mice treated by YKL-40 recombinant protein/neutralizing antibody) and in vitro (macrophages that Ykl40 up-/down-expressed) experiments. The downstream targets were predicted by iTRAQ analysis.

Results: In early-stage human carotid plaques and murine plaques, the YKL-40 expression level had a significant positive correlation with the area of the lesion and a significant negative correlation with the macrophage apoptosis rate. In vivo, the plaque area of aortic roots was significantly larger in the recomb-YKL-40 group than that in IgG group (p = 0.0247) and was significantly smaller in the anti-YKL-40 group than in the IgG group (p = 0.0067); the macrophage apoptosis rate of the plaque in aortic roots was significantly lower in the recomb-YKL-40 group than that in IgG group (p = 0.0018) and was higher in anti-YKL-40 group than that in VC group. In vitro, the activation level of caspase-9 was significantly lower in RAW264.7 with Ykl40 overexpressed than that in controls (p = 0.0054), while the expression level of Aven was significantly higher than that in controls (p = 0.0031). The apoptosis rate of RAW264.7 treated by recomb-YKL40 was significantly higher in the Aven down-regulated group than that in the control group (p < 0.001). The apoptosis inhibitor Aven was confirmed as the target molecule of YKL-40. Mechanistically, YKL-40 could inhibit macrophage apoptosis by upregulating Aven to suppress the activation of caspase-9.
INTRODUCTION

Cardio- and cerebrovascular diseases are the leading causes of mortality worldwide and account for well over 20% of all deaths, according to World Health Organization (WHO) estimates (Mathers and Loncar, 2006; Kim and Johnston, 2011). Statistics show that 9–35% of transient ischemic attacks (TIA) or strokes are associated with extracranial carotid atherosclerosis (Sacco et al., 1995; Wityk et al., 1996). Currently, treatments for carotid artery stenosis are most often performed at the late stage of carotid atherosclerosis, aiming to improve cerebral ischemia symptoms and prevent stroke or other serious ischemic complications. There are no definite effective means to inhibit plaque aggravation in the early stage to date.

Atherosclerosis is universally identified as a progressive inflammatory disease. In its initial stage, apolipoprotein B-containing lipoproteins accumulate in the arterial intima, triggering a chronic inflammatory response dominated by the recruitment of monocyte-derived macrophages (Tabas and Lichtman, 2017). Macrophages engulf lipids and form foam cells, a hallmark of the onset of early-stage atherosclerosis. Then apoptosis occurs and the cellular debris of macrophages is removed by efferocytosis. This programmed cell removal (PrCR) process can reduce the components of atherosclerotic plaque, which would effectively decrease plaque burden and inhibit lesion progression (Tabas, 2005; Vandivier et al., 2006; Gautier et al., 2009; Seimon and Tabas, 2009). Studies have shown that the inhibition of macrophage apoptosis significantly exacerbates the progression of early-stage atherosclerosis (Liu et al., 2005). Though the effect of macrophage apoptosis on atherosclerosis progression is reverse in advanced lesions, it is thought to be caused by impaired efferocytosis of phagocytes in the later-stage lesions (Tabas, 2005; Schrijvers et al., 2007). In our previous research, the impaired efferocytosis function of macrophages induced by the inflammatory factor YKL-40 contributed to enlarging the necrotic core and undermining the stability of later-stage atherosclerotic plaques.

YKL-40, also known as chitinase-3-like protein 1 (CHI3L1), is a 40 kD mammalian glycoprotein, belonging to the conserved mammalian chitinase family but without chitinase activity (Hakala et al., 1993; Rathcke and Vestergaard, 2006). YKL-40 has been identified as a novel biomarker of systemic inflammation and is expressed and secreted by macrophages, vascular smooth muscle cell (VSMC) and neutrophils under pathological conditions (Michelsen et al., 2010). Recent studies have shown that YKL-40 could play an important role in regulating apoptosis, pyroptosis, and activation of inflammasomes, etc. (Lee et al., 2009; Sohn et al., 2010; Chen et al., 2011; Areshkov et al., 2012). YKL-40 is lack of chitinase activity, while it still reserves certain biological function like possessing the carbohydrate-binding motif (CBM), which is considered the potential path that YKL-40 enhancing the AKT phosphorylation (Chen et al., 2011). Our previous research and other studies have found that serum levels of YKL-40 are markedly increased in patients with carotid atherosclerosis, especially in patients with ischemic symptoms (Kjaergaard et al., 2010; Michelsen et al., 2010; Wu et al., 2013). Moreover, a large population study confirmed that elevated plasma YKL-40 levels were positively correlated with an increased risk of ischemic stroke (Kjaergaard et al., 2010). We have known that YKL-40 could aggravate atherosclerosis progression. However, the effect of YKL-40 on the function of macrophages and the PrCR process in plaque and its mechanisms during early-stage atherosclerosis are still not known.

In this study, we focused on the effect of YKL-40 on regulating early-stage atherosclerotic plaque progression and explored its potential mechanisms.

MATERIALS AND METHODS

Human Study Population and Sample Preparation

Early-stage carotid plaques and corresponding blood samples were collected from 16 patients with carotid body tumors and five patients with carotid aneurysm undergoing surgical operations in the Department of Vascular and Endovascular Surgery, Changzheng Hospital, affiliated with the Naval Medical University (Shanghai, People’s Republic of China) between July 2015 and September 2019. The inclusion criteria were patients with inchoate atherosclerosis in the carotid arteries. Exclusion criteria were patients with definite atherosclerotic carotid stenosis and renal/liver failure or other chronic disease that might result in metabolic abnormalities. As previously described, early-stage plaque samples were collected including foam cells and lipid particles accumulating in several pools in the thickening intima. Advanced lesions that had developed a massive, confluent, well-delineated accumulation of extracellular lipid (a lipid core) were excluded (Stary et al., 1994). For this study, all plaque samples were collected from patients intraoperatively, then flushed with phosphate buffered saline (PBS) and immediately stored in liquid nitrogen. All peripheral blood samples were collected before the procedure. Serum was acquired by centrifugation of the peripheral blood at 3,500 rpm for 10 min at room temperature and stored at −80°C before further processing. This research was conducted according to institutional and

Conclusion: YKL-40 inhibits macrophage apoptosis by upregulating the apoptosis inhibitor Aven to suppress the activation of caspase-9, which may impede normal PrCR and promote substantial accumulation in early-stage plaques, thereby leading to the progression of atherosclerosis.
ethical guidelines. Patients’ informed consents were obtained. The study protocol was approved by the Independent Ethics Committee of the Changzheng Hospital affiliated with the Naval Medical University.

Calculating Relative Area and Grouping for Samples
H&E (hematoxylin-eosin) staining was performed on the cross-section of the plaques. The plaque area and total lesion area were calculated according to the staining outcomes, and the percentage of plaque area to total lesion area was counted as the relative area (%) of plaque (Supplementary Figure S1).

In order to compare the results between the groups on the basis of lesion size, all 21 samples were divided into a small group (n = 10) and a large group (n = 11) at the median value (51.32%) of plaque relative area. Baseline information on these patients in the two groups are compared in Supplementary Table S1.

Atherosclerosis Animal Model and In Vivo Administration Protocol
Ldlr−/− mice were bred based on C57BL/6 mice obtained from Jackson Laboratory. Male Ldlr−/− mice were weaned at 3 weeks old and fed a chow diet until 6 weeks old, then a high cholesterol diet (HCD) was maintained (0.4% fat +1.1% cholesterol +18.8% casein, Research Diets, America, D12104C) to construct the diet (HCD) was maintained (0.4% fat +1.1% cholesterol +18.8% casein, Research Diets, America, D12104C) to construct the atherosclerotic model. The atherosclerotic plaque collected from the aorta of Ldlr−/− mice fed a HCD ≤12 weeks were regarded as early-stage lesions, according to the histological morphology and the criterion as previously described (Whitman, 2004).

At 12 weeks old (while HCD feeding has been lasted for 6 weeks), the administration was initiated. Ldlr−/− mice were randomly divided into three groups (n = 5), including the control group (IgG), YKL-40 recombinant protein group (recomb-YKL-40), and YKL-40 neutralizing antibody group (anti-YKL-40). At each week of age, IgG (1 mg/g), YKL-40 recombinant protein (500 ng/g) and YKL-40 neutralizing antibody (1 mg/g) was intraperitoneally injected for six successive weeks, while the high cholesterol diet was continued. Mice were euthanized after administration completed (while HCD feeding has been lasted for 12 weeks) and tissues were collected. Customized YKL-40 neutralizing antibody (Huioi Co., Ltd., Shanghai, China) was extracted from rabbit serum according to previously described (Mizoguchi, 2006) and the titer of the antisera was measured according to the manufacturer’s instructions (Kojima et al., 2016). After mice were euthanized, cold PBS was injected through the left ventricle to flush out blood or thrombus followed by an injection of 4% paraformaldehyde (10 ml per mouse) for internal fixation. The murine aorta tissue (from aortic root to iliac artery) was removed, the aortic root was immediately stored in liquid nitrogen, and the residual part was fixed in 4% formaldehyde at 4°C for further assay.

Histology and Immunofluorescent Staining
The human carotid plaques and murine aortic root were embedded in paraffin or optimal cutting temperature compound, followed by cutting into 5-μm-thick cryosections. H&E and Masson trichome staining was performed to examine plaque morphology. Human early-stage plaques were defined as previously described (Stary et al., 1994), according to the morphological assay. The murine aortic root cryosections and residual aorta tissue were stained with oil-red O for determination of lipids. Immunofluorescence staining was performed as previously described (Kojima et al., 2016).

Briefly, after being blocked in 1% bovine serum albumin (BSA), sections were incubated with primary antibodies: human macrophages labeled with anti-CD68 Ab (Abcam ab201340 1:100); mouse macrophages labeled with anti-MOMA-2 Ab (Abcam ab33451 1:50); and human/mouse YKL-40 labeled with anti-YKL-40 Ab (Abcam ab180569 1:100). After being washed with PBS, the sections were incubated with fluorescein isothiocyanate (FITC)-conjugated secondary antibodies. Nuclei were stained with 4′, 6-diamidino-2-phenylindole (DAPI; 1:2000) for 5 min. After being rinsed three times in PBS, the sections were examined under a fluorescence microscope. The immunostaining was measured by ImageJ software.

Biochemical Assay
Mice were euthanized after being fasted overnight. Murine blood samples were centrifuged for collecting serum. Total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) were measured by enzymatic colorimetric assays using colorimetric kits (Jiancheng, Nanjing, China) with an automatic biochemical analyzer.

Enzyme-Linked Immunosorbent Assay
Serum YKL-40 levels were measured with the related ELISA kits (R&D DC3L10) according to the manufacturer’s instructions.

Measurement of Macrophage Apoptosis Rate Detection in Human and Murine Plaques
Human carotid plaque and murine aortic root sections were double stained for macrophages and apoptotic cells. Macrophages were stained with anti-CD68 Ab (Abcam ab201340 1:100) or anti-MOMA-2 Ab (Abcam ab33451 1:50) antibody and apoptotic cells were stained with TUNEL kits (Progema G3250) according to the manufacturer’s instructions. The proportion of TUNEL+ in CD68+ cells in each sample was calculated as the apoptosis rate of macrophages in the plaque. Nine randomized magnified fields were chosen to measure the apoptosis rate.

Cell Culture
Mouse bone marrow-derived macrophage (BMDM) were isolated from male C57BL/6 mice and differentiated in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin (Invitrogen), and 10 ng/ml murine M-CSF (Peprotech). The murine macrophage cell line RAW264.7 (ATCC, SC-6003) was grown in DMEM growth media containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Invitrogen). Cells were cultured in a 5% CO2 humidified atmosphere at 37°C.

**In Vitro Apoptosis Rate Measurement**

For the adherent cell assays, BMDM were embedded into Lab-Tek® chamber slides (Sigma). Apoptotic BMDM were induced via Ox-LDL (100 μg/ml for 24 h) combined with staurosporine (STS) (1 μM for 4 h). The apoptotic cells were stained with TUNEL kits (Progema G3250) according to the instructions. Nine randomized magnified fields were chosen to measure the apoptosis rate.

For the flow cytometry-based assays, apoptosis-induced BMDM were prepared into cell suspension. Apoptotic BMDM were detected with the FITC Annexin V Apoptosis Detection Kit with PI (BioLegend 640,914), according to the manufacturer’s instructions. Apoptotic cells were quantified via flow cytometry using the FACS verse cell analyzer (Becton-Dickinson).

**Plasmid Transfection**

RAW264.7 were prepared in cell suspension then plated at 1–2 × 10^5 cells/well in a 24-well plate and cultured for 24 h. Commercially available plasmids for over-expressing or silencing Ykl40/Aven (Genechem Co., Ltd., Shanghai, China) were used. Plasmids were transfected using Lipofectamine 3,000 (Invitrogen L3000001) according to the manufacturer’s instructions. Cells were passaged or harvested for further experiments 48–72 h after transfection.

**iTRAQ Labeling**

iTRAQ-based proteomics analysis (Genechem Co., Ltd., Shanghai, China) were performed to screen out the potential downstream target molecules of YKL-40. Three biological replicates were used for global proteome analysis. BMDM was treated with YKL-40 (500 ng/ml) or IgG as a control for 24 h to assay the potential pathways involved. We collected 20 mg protein from each sample and loaded into 12% SDS-PAGE for electrophoresis. The samples then underwent filter-aided sample preparation and were dissolved in 5X dissolution buffer. Then 100 μg peptide fragments from each sample were labeled with iTRAQ-8plex reagents according to the protocol from AB SCIEX. The labeled peptides were separated by high-performance liquid chromatography (Agilent 1,260 Infinity II HPLC), followed by mass spectrometric analysis and identification. The raw data were processed with Mascot 2.5 software and Proteome Discoverer 2.1 to search the database. The experiment had been performed in our previous research, and the results were further explored in this study. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium with identifier PXD028305 via the PRIDE partner repository.

**Western Blot Assay**

Cells and homogenated human plaques were lysed in RIPA lysis buffer (ThermoFisher) for 60 min at 4°C. Protein samples were subjected to 10% Bis-Tris gels, electrophoresed, transferred to Immobilon-FL membranes (Millipore), and probed with the indicated primary antibody: caspase-3 (CST 9662S), cleaved caspase-3(Asp175) (CST 9661T), caspase-9 (CST 9508T), Aven (CST 2300S), Akt (CST 9272S), Phospho-Akt (Thr308) (CST 13038T), and β-Actin (CST 4970S), followed by incubation with horseradish peroxidase-conjugated secondary antibodies. Protein bands were visualized using an LAS 3000 Imag (Fujifilm) and were quantified using Image (Image) software (Image) 1.51U, Fuji edition.

**Ribonucleic Acid Extraction and Quantitative Real-Time Polymerase Chain Reaction**

RNA was isolated from samples and cells using the RNeasy Kit (QIAGEN), and cDNA was synthesized from RNA (500 ng-1 μg per reaction) using Prime Script RT Master Mix (TaKaRa 2,621). Quantitative Real-time PCR (qRT-PCR) was performed using the LightCycler 480 Real-Time PCR System (Roche) and SYBR Green I Master (Rohe 94,707,516,001). Primer sets used are listed in supplemental data (Supplementary Table S1).

**Statistics Analysis**

Independent experiments were replicated at least three times. All results are represented as mean ± SEM. Normality was determined using D’Agostino-Pearson and/or Shapiro-Wilk normality testing. p-values for normally distributed data were calculated using Student’s t-test or one-way ANOVA analysis. p-values for non-normally distributed data were calculated using the Mann-Whitney U test. Percentages were analyzed with Chi-square testing or Fisher’s exact test. Correlation coefficients (r) and related p-values were calculated using the Pearson product-moment correlation analysis. Statistical analysis was performed using Graphpad Prism 8.1. A p-value of <0.05 was deemed statistically significant.

**RESULTS**

**Positive Correlation Was Determined Between Expression Level of YKL-40 and Carotid Early-Stage Plaque Area**

The expression level of YKL-40 in the large group of human subjects was significantly higher than in the small group, according to immunohistochemical staining (p = 0.0034, Figures 1A,B). Significant positive correlation was confirmed between the Ykl40 expression level in the plaque tissues and relative area of plaques (r = 0.6334, p = 0.0021, Figure 1D). Although the mean of Ykl40 expression level was higher in the large group than in the small group, the difference was not significant (p > 0.05, Figure 1C), which may be due to the relatively low expression level of Ykl40 in plaques. However,
the expression level of YKL-40 in serum, which was detected by enzyme-linked immunosorbent assay (ELISA), was significantly higher in the large group than in the small group \( (p = 0.0447) \) and was significantly positively correlated with plaque relative area \( (r = 0.6383, p = 0.0018) \). These results indicated the positive correlation between the expression level of YKL-40 and the relative area of early-stage carotid plaque.

Moreover, the location of YKL-40 had a significant correlation with CD68 in plaque tissues according to immunohistochemical staining \( (p = 0.0447) \) and was significantly positively correlated with plaque relative area \( (r = 0.6383, p = 0.0018) \). The result suggests the potential association between YKL-40 and macrophages.

No Differences in Weight or Lipid Metabolism Among Ldlr\(^{-/-}\) Mice of Three Groups

Weights of all Ldlr\(^{-/-}\) mice in IgG group, YKL-40 recombinant protein group (recomb-YKL-40), and YKL-40 neutralizing antibody group (anti-YKL-40) were monitored and recorded weekly from the last day before intervention to the last day before harvest. Sera from all these mice were collected after euthanasia to test blood lipid levels including total cholesterol (TCHO), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). No statistical differences in weight or blood lipid levels of mice were found among the three groups, which indicated that the nutrition status and lipid metabolism of Ldlr\(^{-/-}\) mice were not affected by the intervention of the YKL-40 recombinant protein or YKL-40 neutralizing antibody \( (p > 0.05,\) Figures 3A,B).
16 weeks, respectively, to obtain the tissue samples, including aortic root and aortic arch. H&E and Masson staining were performed on the aortic root to measure the relative area of plaque. We detected the expression level of Ykl40 in aortic arch tissues by qRT-PCR. Evidently, atherosclerotic plaques were formed on aortic roots at all three time periods, which confirmed the success of model construction (Figure 3C). Meanwhile, both the relative plaque area in the aortic root and Ykl40 expression level in the aortic arch showed a consistently increasing trend as the HCD feeding time increased. The result confirmed the positive correlation between the progression of the plaque area and expression level of YKL-40 in Ldlr−/− mice (Figures 3D,E).

**YKL-40 Resulted in Progression of Atherosclerotic Plaque in Ldlr−/− Mice**

H&E, Masson, and oil-Red O staining were performed on aortic roots, and the plaque area as well as the lipid area were measured in the three mice groups (IgG, YKL-40 protein, YKL-40 neutralizing antibody) (Figure 4A). Oil-red O staining was performed on the whole aorta to measure the plaque relative area as well (Figure 4D). The plaque area in the aortic root was significantly larger in the recombinant-YKL-40 group than that in IgG group (p = 0.0247) and was significantly smaller in the anti-YKL-40 group than in the IgG group (p = 0.0067, Figure 4B). The lipid area was significantly larger in the recombinant-YKL-40 group than that in the IgG group (p = 0.0028) and in the anti-YKL-40 group.
Similarly, the plaque area of the whole aorta was significantly larger in the recomb-YKL-40 group than that in the IgG group ($p = 0.0126$) and was significantly smaller in the anti-YKL-40 group than in the IgG group ($p = 0.0464$, Figure 4E). The results unequivocally confirmed that YKL-40 could result in progression of atherosclerotic plaque in Ldlr$^{-/-}$ mice, including lesion progression and lipid accumulation.

**YKL-40 Inhibited Apoptosis of Macrophages in Atherosclerotic Plaque of Ldlr$^{-/-}$ Mice**

Macrophages and apoptotic cells in aortic root plaques of Ldlr$^{-/-}$ mice were simultaneously assayed via immunofluorescent staining (for MOMA-2) and TUNEL, respectively (Figure 4G). The percentage of TUNEL$^+$ in MOMA-2$^+$ cells was calculated as the apoptosis rate of macrophages in each sample. The apoptosis rate of macrophages in aortic root plaques was significantly lower in the recomb-YKL-40 group than in the IgG group ($p = 0.0018$) and anti-YKL-40 group ($p = 0.001$). However, the rate was not significantly higher in the anti-YKL-40 group than in the VC group ($p = 0.0513$, Figure 4F). The results indicated that YKL-40 exerts an inhibitory effect on apoptosis of macrophages in atherosclerotic plaques in Ldlr$^{-/-}$ mice.

**YKL-40 Inhibited Apoptosis of Macrophages In Vitro**

BMDM apoptosis was induced by treatment with oxidized low-density lipoprotein (OX-LDL) $100 \mu g/ml$ for $24 \text{ h}$ accompanied by staurosporine $4 \mu M$ for $4 \text{ h}$. After treatment with YKL-40 recombinant protein ($500 \text{ ng/ml}$) for $24 \text{ h}$ on apoptosis BMDM, TUNEL detection was performed on the cells in situ (Figure 5A). The staining result showed that the apoptosis rate of BMDM treated by YKL-40 recombinant protein was significantly lower than that in the apoptosis model ($p = 0.0161$). Flow cytometry (FCM) was performed while another cell group, the apoptosis BMDM synchronously treated by YKL-40 recombinant protein and YKL-40 neutralizing antibody ($500 \mu g/ml$) for $24 \text{ h}$, was added (Figure 5B). The FCM result showed that the
apoptosis rate of BMDM in the YKL-40 recombinant protein treated group was significantly lower than that in the apoptosis model group ($p = 0.0008$) and was significantly higher in the YKL-40 neutralizing antibody extra treated group than in the YKL-40 recombinant protein treated group ($p = 0.0042$). Moreover, the apoptosis rate of RAW264.7 was detected by FCM after overexpressing or silencing Ykl40. FCM results indicated the apoptosis rate of RAW264.7 was significantly lower in the Ykl40 overexpressed group than that in apoptosis model group ($p = 0.0205$) and Ykl40 knockdown group ($p = 0.0197$), but there was no significant difference between the Ykl40 knockdown group and the model group ($p > 0.05$, Figure 5C). These results indicated that YKL-40 has an inhibitory effect on apoptosis of macrophages in vitro.

**YKL-40 Inhibited Macrophage Apoptosis Via Suppressing Activation of Caspase-9**

An iTRAQ-based proteomics analysis was performed on BMDM to screen out the potential downstream target molecules of YKL-40 in regulating macrophage apoptosis. Among all the apoptosis-regulating molecules, Casp9 ($p = 0.0311$), Casp8 ($p = 0.0399$), Bak-1 ($p = 0.0014$), and Dap ($p = 0.0041$), all of which have the effect of promoting apoptosis, were significantly down-regulated in BMDM treated by YKL-40 recombinant protein, while the apoptosis inhibitor Aven was significantly up-regulated ($p = 0.0251$, Figure 6A). A Volcano Plot revealed that the most significant fold change (FC) on expression level among these molecules was Casp9 (FC = 0.6411), which was followed by Aven (FC = 1.3006, Figure 6B), Bak1 and Dap.

The expression level of activated caspase-9 in BMDM were detected by western blot. The value of cleaved caspase-9/β-actin were calculated as activation level of caspase-9, which was significantly lower in the recomb-YKL-40 group than in IgG group ($p = 0.0038$, $p = 0.0419$, Figure 6C).

These results were verified in aortic arch tissues of Ldlr$^{-/-}$ mice. The activation levels of caspase-3 and caspase-9 were significantly lower in the recomb-YKL-40 group than in the IgG group ($p = 0.0038$, $p = 0.0316$) and that in the anti-YKL-
FIGURE 5 | (A) TUNEL detection performed on BMDM. The apoptosis rate of BMDM treated by YKL-40 recombinant protein was significantly lower than that in the apoptosis model that treated by Ox-LDL accompanied by staurosporine (p = 0.0161). (B) FCM indicated the apoptosis rate of BMDM was significantly lower in the recombin-YKL-40 group than that in apoptosis model group (p = 0.0006), as well as that in anti-YKL-40 group (p = 0.0042). (C) FCM indicated the apoptosis rate of RAW264.7 was significantly lower in the Ykl40↑ group than that in apoptosis model [p = 0.0205] and Ykl40↓ group [p = 0.0197].

FIGURE 6 | (A,B) iTRAQ-based proteomics analysis. (A) Apoptosis promotors Casp9, Casp8, Bak1, and Dap were significantly down-regulated by YKL-40, while the apoptosis inhibitor Aven was significantly up-regulated. (B) Volcano Plot. Molecules down-regulated by YKL-40 are presented in the upper left area (green down arrow) while those up-regulated are shown in the upper right area (red up arrow), and those involved in apoptosis regulation are marked with up/down solid arrows. The most significant fold change (FC) on the expression level of these molecules was caused by Casp9 (FC = 0.6411), followed by Aven (FC = 1.3006). (C,D) Caspase-9 expression levels detected in BMDM and aorta tissues of Ldlr−/− mice. YKL-40 significantly down-regulated the activation level of caspase-9. (E) in RAW264.7, which was upregulated by Ykl-40, the activation level of caspase-9 was significantly lower than that in control group (p = 0.0054) while the expression level of Aven was significantly higher than in controls (p = 0.0001). There was no significant difference in caspase-9 activation and Aven expression level between the Ykl40 downregulated group and normal controls (p > 0.05). (F) Genetic expression relative fold changes of Casp9, Dap, Aven and Bak1. No significant difference was indicated on Casp9 in BMDM after being treated by YKL-40 recombinant protein, but Aven was significantly up-regulated. (G) Casp9, Aven expression levels were significantly upregulated in Ykl40 upregulated RAW264.7 (p = 0.0154, p < 0.0001) and downregulated in the Ykl40 downregulated group (p = 0.0039, p = 0.0037).
40 group ($p = 0.0099, p = 0.0420$), but there was no significant difference between the anti-YKL-40 group and the IgG group ($p > 0.05$, Figure 6D).

However, there was no significant difference in the genetic expression level of Casp9 between the recomb-YKL-40 group and IgG group in BMDM ($p > 0.05$). At the same time, the expression level of Aven was significantly higher in the recomb-YKL-40 group than in the IgG group ($p = 0.0048$, Figure 6F).

**YKL-40 Inhibited Macrophage Apoptosis Via Suppressing Caspase-9 Activation by Up-Regulating Aven**

In RAW264.7 with Ykl40 overexpressed, the activation level of caspase-9 was significantly lower than that in the control group ($p = 0.0054$), while the expression level of Aven was significantly higher than in normal controls ($p = 0.0031$, Figure 6E). However, there was no significant difference on caspase-9 activation and Aven expression level between Ykl40 downregulated group and normal control ($p > 0.05$). Interestingly, although the Aven expression level corresponded with protein expression, the expression level of Casp9 was significantly upregulated in Ykl40-upregulated Raw264.7 and downregulated in the Ykl40 downregulated group compared with normal controls ($p = 0.0154, p = 0.0039$), which was quite contrary to protein presentation (Figure 6F). The results indicated the suppression effect on caspase-9 activation of YKL40 was limited to the protein modification process, while Aven could be the potential target molecule.

**Regulatory Role of Aven in YKL-40 Inhibition of Macrophage Apoptosis**

We modified the expression of Aven in RAW264.7 to confirm the effect of Aven in YKL-40 inhibition of apoptosis. FCM analysis was performed to detect the apoptosis rate after TUNEL staining. Results showed that the apoptosis rate of RAW264.7 in the recomb-YKL-40 group was certainly significantly lower than that in the apoptosis model group ($p < 0.001$). When Aven expression was downregulated, the
apoptosis rate of RAW264.7 was significantly increased compared to that in the recomb-YKL-40 group \( (p < 0.001, \text{Figure 7}) \). The results suggested that the inhibitory effect of YKL-40 on macrophage apoptosis was mediated by its suppression of Aven.

**DISCUSSION**

In this study, the major findings are as follows: 1) the expression level of YKL-40 was positively correlated with the lesion size in early-stage carotid plaque; 2) the expression level of YKL-40 was negatively correlated with the macrophage apoptosis rate in early-stage carotid plaque; 3) YKL-40 treatment could suppress the apoptosis of murine macrophages and promote the progression of early-stage plaque in mice; 4) YKL-40 could inhibit the activation of the apoptosis promoter caspase-9 by upregulating the expression of apoptosis inhibitor Aven to suppress the apoptosis of macrophages.

Experimental results on the samples of early-stage carotid plaque patients indicated that the expression level of YKL-40 both in plaque tissues and in peripheral serum was positively correlated with the plaque area, suggesting that YKL-40 was significantly related to the progression of early-stage carotid plaques. Moreover, the correlation of location between YKL-40 and macrophages in plaques suggested its biological function in connection with macrophages. The results of experiments *in vivo* and *in vitro* confirmed that YKL-40 could not only promote the progression of atherosclerotic plaque but also suppress the apoptosis of macrophages in plaques.

Studies focused on advanced atherosclerotic lesions indicated that the elevated apoptosis rate of macrophages could enlarge the necrotic core (NC) and induce the instability of atherosclerotic plaques (Gautier et al., 2009). Many researchers are convinced that the enlarged NC has more to do with the impaired efferocytosis in later-stage atherosclerosis than macrophage apoptosis in plaques (Tabas, 2005; Schrijvers et al., 2007). However, in this study, we confirmed that in the early-stage plaque, impaired macrophage apoptosis induced by YKL-40 could certainly aggravate the atherosclerotic lesion.

Areshkov et al. thought that YKL-40 is a strong inductor of MAPK and PI3K signaling pathways, what would mediate the phosphorylation of ERK1/2 (Areshkov et al., 2012). Lee et al. have found that YKL-40 could inhibit apoptosis by inhibiting Fas (CD95) expression, activating the PKB/AKT and apoptosis inhibitor Faim3 (TOSO) (Lee et al., 2009). Unfortunately, like the most of other studies, they didn’t refer to the specific mechanism of YKL-40 regulating the apoptosis pathways. However, based on the results of the experiments on molecular mechanisms in this study, we might propose a novel apoptosis-regulated pathway of YKL-40 depending on caspases cascade and apoptosis inhibitor Aven. We analyzed the differentially expressed apoptosis-related protein molecules in BMDM through iTRAQ analysis. The results showed that the apoptosis promoters caspase-9, caspase-8, BAK, and DAP were significantly down-regulated in BMDM treated by YKL-40 while the apoptosis inhibitor Aven was significantly up-regulated. Results of the protein expression level of caspase-9, an important initial promoter of the caspase cascade, was detected in BMDM and mice tissues, consistent with the iTRAQ analysis. However, the mRNA expression level of *Casp9* detected in BMDM treated by YKL-40 was contrary to protein detection. We repeatedly confirmed these phenomena on RAW264.7 whose *Ykl40* has been up/down-regulated. The results suggested that YKL40 may not directly regulate the expression of caspase-9 but may inhibit the activation from procaspase-9 to caspase-9. Meanwhile, there was no significant difference in the mRNA expression level of BAK and DAP, while Aven was significantly up-regulated in BMDM treated by YKL-40.

Most apoptosis processes are facilitated by the activation of the caspase family (Thornberry and Lazebnik, 1998). Some caspases are cleaved and activated by other caspases or regulated by bridging or regulatory factors, such as Bcl-2, a prototype of the anti-apoptotic protein family, which could suppress caspase-mediated cell death (Adams and Cory, 1998; Srinivasula et al., 1998; Yang et al., 1998). Studies have identified Aven as a new apoptosis inhibitor that can bind both Bcl-XL, a member of Bcl-2 family, and caspase regulator Apaf-1, suppressing apoptosis induced by Apaf-1 plus caspase-9 (Chau et al., 2000). In this study, we confirmed by silencing or over-expressing *Ykl40* in RAW264.7 that Aven was significantly
regulated by YKL40 in both protein and mRNA expression levels. Moreover, flow cytometry on RAW264.7 confirmed that the suppressive effect of YKL-40 on macrophage apoptosis was significantly impaired when Aven was down-regulated.

Based on the above results, we suggest that YKL-40 can up-regulate the expression of Aven which could suppress the activation of caspase-9 by interfering with APAF-1 binding to it, then inhibit the activation of the caspase cascade and finally inhibit the apoptosis of macrophages. Moreover, in our previous study, we have found YKL-40 also exert an inhibiting effect on macrophage efferocytosis, a key part of PrCR. Which suggest YKL-40 might play an important role in impairing the entire process of PrCR in atherosclerotic lesion. However, it is ambiguous that YKL-40 promotes atherosclerosis mainly on account of its inhibiting effect on apoptosis or efferocytosis, and the specific mechanism of YKL-40 up-regulating Aven expression remains elusive. Which are worthy of further research and discussion. In addition, administration process that we performed in this study might provide more solid evidence on the global effect of YKL-40 affecting the plaque progression than the local effect in vivo. However, it is our conjecture based on existing positive results that the YKL-40 might impair the PrCR to impact plaque macrophages and then aggravate atherosclerosis. Locally intervening experiments would be arranged to further confirm the local effect of YKL-40 in the future study.

In conclusion, YKL-40 might suppress the apoptosis of macrophages by inhibiting the activation of apoptosis promoter caspase-9 via up-regulating the expression of the apoptosis inhibitor Aven. Inhibited apoptosis of macrophages results in impaired PrCR in plaque. The accumulation of macrophages that should have been apoptotic and removed by efferocytosis could enlarge the plaques and aggravate early-stage atherosclerosis (Figure 8).

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: ProteomeXchange, PXD028305.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Independent Ethics Committee of the Changzheng Hospital affiliated with the Naval Medical University. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by Independent Ethics Committee of the Changzheng Hospital affiliated with the Naval Medical University.

AUTHOR CONTRIBUTIONS

HW performed most experiments and completed the original manuscript; LY and WC made the important cooperations in this study; ZS, BJ and LM participated in collecting information of patients, pre-processing samples and assisting complete the experiments; QL and CY provided the crucial guidances and made final decision in this study.

FUNDING

This study was funded by the National Natural Science Foundation of China (81,870,347), the Specifically Invited Professor of Oriental Scholar of Shanghai Colleges and Universities Tracking Program (GZZ2016008), the Program of Excellent Academic Leader of Shanghai (20XD1404900), Advanced Achievement Cultivation Program of the Naval Military Medical University (2018-CGPZ-B05), and the Advanced Achievement Cultivation Program of Changzheng Hospital (2020YCGPZ-205).

ACKNOWLEDGMENTS

We would like to thank Clinical Research Institute of Integrative Medicine, Yueyang Hospital, Shanghai University of Traditional Chinese Medicine, and all of the researchers for providing technical support and cooperation throughout the study.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2021.752773/full#supplementary-material

REFERENCES

Adams, J. M., and Cory, S. (1998). The Bcl-2 Protein Family: Arbiters of Cell Survival. Science 281 (5381), 1322–1326. doi:10.1126/science.281.5381.1322
Areshkov, P. O., Avdieiev, S. S., Balynska, O. V., Leroith, D., and Kavsan, V. M. (2012). Two Closely Related Human Members of Chitinase-like Family, CHI3L1 and CHI3L2, Activate ERK1/2 in 293 and U373 Cells but Have the Different Influence on Cell Proliferation. Int. J. Biol. Sci. 8 (1), 39–48. doi:10.7150/ijbs.8.39
Chau, B. N., Cheng, E. H.-Y., Kerr, D. A., and Hardwick, J. M. (2000). Aven, a Novel Inhibitor of Caspase Activation, Binds Bcl-xl and Apaf-1. Mol. Cell 6 (1), 31–40. doi:10.1016/s1097-2765(05)80021-3
Chen, C.-C., Llado, V., Witztum, J. L., Ouzilleau, B., Miller, E. R., Saint-Charles, F., et al. (2009). Macrophage Apoptosis Exerts Divergent Effects on Atherogenesis as a Function of Lesion Stage. Circulation 119 (13), 1795–1804. doi:10.1161/CIRCULATIONAHA.108.806158

Frontiers in Cell and Developmental Biology | www.frontiersin.org 12 December 2021 | Volume 9 | Article 752773
Hakala, B. E., White, C., and Recklies, A. D. (1993). Human Cartilage Gp-39, a Major Secretory Product of Articular Chondrocytes and Synovial Cells, Is a Mammalian Member of a Chitinase Protein Family. *J. Biol. Chem.* 268 (34), 25803–25810. doi:10.1016/0021-9258(93)74461-5

Kim, A. S., and Johnston, S. C. (2011). Global Variation in the Relative burden of Stroke and Ischemic Heart Disease. *Circulation* 124 (3), 314–323. doi:10.1161/CIRCULATIONAHA.111.018820

Kjærgaard, A. D., Bojesen, S. E., Johansen, J. S., and Nordestgaard, B. G. (2010). Elevated Plasma YKL-40 Levels and Ischemic Stroke in the General Population. *Ann. Neurol.* 68 (5), 672–680. doi:10.1002/ana.22220

Kojima, Y., Volkmer, J.-P., McKenna, K., Civelek, M., Lusis, A. J., Miller, C. L., et al. (2010). Role of Breast Regression Protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced Tissue Responses and Apoptosis. *J. Exp. Med.* 206 (5), 1149–1166. doi:10.1084/jem.20081271

Lee, J., Hartl, D., Lee, G. R., Koller, B., Matsuura, H., Da Silva, C. A., et al. (2011). Global Variation in the Relative burden of Stroke and Ischemic Heart Disease. *J. Lipid Res.* 52 (1), 14–22.

Michelsen, A. E., Rathcke, C. N., Skjelland, M., Holm, S., Ranheim, T., Krogh-Sorensen, K., et al. (2010). Increased YKL-40 Expression in Patients with Carotid Atherosclerosis. *Atherosclerosis* 211 (2), 589–595. doi:10.1016/j.atherosclerosis.2010.02.035

Mizoguchi, E. (2006). Chitinase 3-like-1 Exacerbates Intestinal Inflammation by Enhancing Bacterial Adhesion and Invasion in Colonic Epithelial Cells. *Gastroenterology* 130 (2), 398–411. doi:10.1053/j.gastro.2005.12.007

Rathcke, C. N., and Vestergaard, H. (2006). YKL-40, a New Inflammatory Marker with Relation to Insulin Resistance and with a Role in Endothelial Dysfunction and Atherosclerosis. *Inflamm. Res.* 55 (6), 221–227. doi:10.1007/s00011-006-0076-y

Sacco, R. L., Kargman, D. E., Gu, Q., and Zamanillo, M. C. (1995). Race-Ethnicity and Determinants of Intracranial Atherosclerotic Cerebral Infarction. *Stroke* 26 (1), 14–20. doi:10.1161/01.str.26.1.14

Schrijvers, D., Demeyer, G., Herman, A., and Martinet, W. (2007). Phagocytosis in Atherosclerosis: Molecular Mechanisms and Implications for Plaque Progression and Stability. *Cardiovasc. Res.* 73 (3), 470–480. doi:10.1093/cr/73.3.470

Seimlon, T., and Tabas, I. (2009). Mechanisms and Consequences of Macrophage Apoptosis in Atherosclerosis. *J. Lipid Res.* 50 (Suppl.1), S382–S387. doi:10.1194/jlr.R900032-JLR200

Sohn, M. H., Kang, M.-J., Matsuura, H., Bhandari, V., Chen, N.-Y., Lee, C. G., et al. (2010). The Chitinase-like Proteins Breast Regression Protein-39 and YKL-40 Regulate Hyperoxia-Induced Acute Lung Injury. *Am. J. Respir. Crit. Care Med.* 182 (7), 918–928. doi:10.1164/rcrm.200912-1793OC

Srinivasula, S. M., Ahmad, M., Fernandes-Alnemri, T., and Alnemri, E. S. (1998). Autoactivation of Procaspase-9 by Apaf-1-Mediated Oligomerization. *Mol. Cell.* 1 (7), 949–957. doi:10.1016/S1097-2765(00)80095-7

Stary, H. C., Chandler, A. B., Glagov, S., Guyton, J. R., Insull, W., Jr., Rosenfeld, M. E., et al. (1994). A Definition of Initial, Fatty Streak, and Intermediate Lesions of Atherosclerosis. A Report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation* 89 (5), 2462–2478. doi:10.1161/01.cir.89.5.2462

Tabas, I. (2005). Consequences and Therapeutic Implications of Macrophage Apoptosis in Atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* 25 (11), 2255–2264. doi:10.1161/01.ATV.0000148578.04864.9f

Tabas, I., and Lichtman, A. H. (2017). Monocyte-Macrophages and T Cells in Atherosclerosis. *Immunity* 47 (4), 621–634. doi:10.1016/j.immuni.2017.09.008

Thornberry, N. A., and Lazebnik, Y. (1998). Caspases: Enemies within. *Science* 281 (5381), 1312–1316. doi:10.1126/science.281.5381.1312

Vandivier, R. W., Henson, P. M., and Douglas, I. S. (2006). Burying the Dead. *Chest* 129 (6), 1673–1682. doi:10.1378/chest.129.6.1673

Whitmam, S. C. (2004). A Practical Approach to Using Mice in Atherosclerosis Research. *Clin. Biochem. Rev.* 25 (1), 81–93.

Wityk, R. J., Lehman, D., Klag, M., Coresh, J., Ahn, H., and Litt, B. (1996). Race and Sex Differences in the Distribution of Cerebral Atherosclerosis. *Stroke* 27 (11), 1974–1980. doi:10.1161/01.str.27.11.1974

Wu, Y., Tao, Z., Song, C., Jia, Q., Bai, J., Zhi, K., et al. (2013). Overexpression of YKL-40 Predicts Plaque Instability in Carotid Atherosclerosis with CagA-Positive *Helicobacter pylori* Infection. *PLoS One* 8 (4), e59996. doi:10.1371/journal.pone.0059996

Yang, X., Chang, H. Y., and Baltimore, D. (1998). Autoproteolytic Activation of Pro-caspases by Oligomerization. *Mol. Cell* 1 (2), 319–325. doi:10.1016/s1097-2765(00)80032-5

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2021 Huan, Yandong, Chao, Sili, Jun, Mingfang, Yu and Lefeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**